Prime Medicine, Inc. (PRME)
NASDAQ: PRME · IEX Real-Time Price · USD
5.31
-0.27 (-4.76%)
Jul 19, 2024, 4:00 PM EDT - Market closed
Company Description
Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address the spectrum of diseases by deploying gene editing technology.
The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence.
It has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome.
The company was incorporated in 2019 and is based in Cambridge, Massachusetts.
Prime Medicine, Inc.
| Country | United States |
| Founded | 2019 |
| IPO Date | Oct 20, 2022 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 234 |
| CEO | Dr. Keith Michael Gottesdiener M.D., Ph.D. |
Contact Details
Address: 60 First St. Cambridge, Massachusetts 02141 United States | |
| Phone | 617-465-0013 |
| Website | primemedicine.com |
Stock Details
| Ticker Symbol | PRME |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $17.00 |
| CIK Code | 0001894562 |
| CUSIP Number | 74168J101 |
| ISIN Number | US74168J1016 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Keith Michael Gottesdiener Ph.D. | President, Chief Executive Officer, Secretary and Director |
| Dr. Ann L. Lee Ph.D. | Chief Technical Officer |
| Richard Brudnick | Chief Business Officer |
| Dr. Andrew Anzalone M.D., Ph.D. | Co-Founder and Head of Prime Editing Platform |
| Dr. David R. Liu Ph.D. | Co-Founder and Chair of Scientific Advisory Board |
| Dr. Allan Reine M.D. | Chief Financial Officer |
| Dr. Meredith Goldwasser | Senior Vice President and Head of Strategy and Corporate Operations |
| Carman Alenson CPA, M.B.A. | Senior Vice President of Finance and Chief Accounting Officer |
| Dr. Jeremy S. Duffield M.D., Ph.D. | Chief Scientific Officer |
| Dr. Karen Brown J.D., Ph.D. | Senior Vice President of Intellectual Property and Legal Affairs |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 12, 2024 | 8-K | Current Report |
| May 21, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| May 21, 2024 | 8-K | Current Report |
| May 10, 2024 | 10-Q | Quarterly Report |
| May 10, 2024 | 8-K | Current Report |
| Apr 29, 2024 | ARS | Filing |
| Apr 29, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 29, 2024 | DEF 14A | Other definitive proxy statements |
| Apr 19, 2024 | PRE 14A | Other preliminary proxy statements |
| Mar 1, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |